Evaluation of a Cathepsin-Cleavable Peptide Linked Radioimmunoconjugate of a Panadenocarcinoma MAb, m170, in Mice and Patients

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 1, 2004, Pages 85-92

  DeNardo, Gerald L ^a,b   DeNardo, Sally J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Molecular Cancer Institute   (United States)

Author keywords

Antibody; Cancer; Indium 111; Linker; Radioimmunotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 2 IMINOTHIOLANE MONOCLONAL ANTIBODY M170 CONJUGATE IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID GLYCYLGLYCYLGLYCYL MONOCLONAL ANTIBODY M170 CONJUGATE IN 111; 2 IMINOTHIOLANE 2 [4 (BROMOACETAMIDO)BENZYL] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID MONOCLONAL ANTIBODY M170 CONJUGATE IN 111; ANTIBODY CONJUGATE; CATHEPSIN; PEPTIDE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST CANCER; CALCULATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONJUGATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TISSUE LEVEL; ENZYME ACTIVE SITE; FEMALE; HUMAN; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIOACTIVITY;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CATHEPSINS; CHELATING AGENTS; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; IMMUNOCONJUGATES; INDIUM RADIOISOTOPES; LIVER; MALE; MICE; MICE, NUDE; PEPTIDES; PROSTATIC NEOPLASMS;

EID: 1542743561     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497804773391720     Document Type: Conference Paper

References (22)

1. Moi MK, Meares CF, DeNardo SJ. The peptide way to macrocyclic bifunctional chelating agents: Synthesis of 2-(p-Nitrobenzyl)-1,4,7,10-tetraazacyclododecane -N,-N′,N″,N‴ -tetraacetic acid and study of its yttrium (III) complex. J Am Chem Soc 1988;110:6266.
2. Deshpande SV, DeNardo SJ, Kukis DL, et al. Yttrium-90-labeled monoclonal antibody for therapy: Labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med 1990;31:473.
3. 111In-labeled monoclonal antitumor antibodies in normal animals and nude-mouse human tumor models. Cancer Res 1983;43:5347.
4. Pimm MV, Perkins AC, Baldwin RW. Differences in tumor and normal tissue concentrations of iodine and indium labeled monoclonal antibody. II. Biodistribution studies in mice with human tumor xenografts. Eur J Nucl Med 1985;11:300.
5. Hnatowich DJ. Antibody radiolabeling, problems and promises. Nucl Med Biol 1990;17:49.
6. Li M, Meares CF. Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates. Bioconjug Chem 1993;4:275.
7. DeNardo GL, Kroger LA, Meares CF, et al. Comparison of 1,4,7,10-tetraazacyclododecaine-N,N′,N″,N‴-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts. Clin Cancer Res 1998;4: 2483.
8. DeNardo SJ, Richman CM, Goldstein DS, et al. Yttrium-90/Indium-111-DOTA-peptide-Chimeric L6: Pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Anticancer Res 1997;17:1735.
9. 90Y-linked monoclonal MUC-1 antibodies. Crit Rev Oncol Hematol 2001;38: 26.
10. DeNardo GL, DeNardo SJ, Peterson JK, et al. Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates. Clin Cancer Res 2003;9: 3865s.
11. DeNardo SJ, DeNardo GL, Yuan A, et al. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: Comparison of radiation dosimetry for 1,4,7,10-Tetraazacyclododecane-N,N′, N″,N‴ -Tetraacetic Acid (DOTA)-peptide versus 2-IT-DOTA monoclonal antibody linkage for RIT. Clin Cancer Res 2003;9:3938s.
12. Longenecker BM, Willans DJ, MacLean GD, et al. Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens of human cancers. J Natl Cancer Inst 1987;78:489.
13. Alexander C, Villena-Heinsen CE, Trampert L, et al. Radioimmunoscintigraphy of ovarian tumors with technetium-99m labelled monoclonal antibody-170: First clinical experiences. Eur J Nucl Med 1995;22:645.
14. McCall MJ, Diril H, Meares CF. Simplified method for conjugating macrocyclic bifunctional chelating agents to antibodies via 2-iminothiolane. Bioconjug Chem 1990;1:222.
15. Li M, Meares CF, Zhong GR, et al. Labeling monoclonal antibodies with 90yttrium- and 111indium-DOTA chelates: A simple and efficient method. Bioconjug Chem 1994;5:101.
16. Li M, Meares CF, Salako Q, et al. Prelabeling of chimeric monoclonal antibody L6 with 90Yttrium- and 111Indium-1,4,7,10-tetraazacyclododecane-N,N′, N″,N‴ -tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy. Cancer Res 1995;55 Suppl:5726.
17. 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. J Nucl Med 2000;41:952.
18. DeNardo SJ, O'Grady LF, Macey DJ, et al. Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy. Int J Rad Appl Instrum 1991;18:621.
19. Erwin WD, Groch MW, Macey DJ, et al. A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy. Nucl Med Biol 1996;23:525.
20. Peterson JJ, Meares CF. Cathepsin substrates as cleavable peptide linkers on bioconjugates, selected from a fluorescence quench combinatorial library. Bioconjug Chem 1998;9:618.
21. Peterson JJ, Meares CF. Enzymatic cleavage of peptide-linked radiolabels from immunoconjugates. Bioconjug Chem 1999;10:553.
22. Sancho J, Gonzalez E, Escanero JF, et al. Binding kinetics of monomeric and aggregated IgG to Kupffer cells and hepatocytes of mice. Immunology 1984;53: 283.